Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial.
Dodwell
D
D
Coombes
G
G
Bliss
J M
JM
Kilburn
L S
LS
Johnston
S
S
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D047072:Aromatase Inhibitors / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D002986:Clinical Trials as Topic; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D000077267:Fulvestrant; D004958:Estradiol